Press release BoxID: 807713 (GILUPI GmbH)
  • Hermannswerder 20a
  • 14473 Potsdam
  • Contact person
  • Claudia Chudak
  • +49 (331) 5818478-5

GILUPI Strengthens Executive Team - Appoints Dr. Jens Pfannkuche as General Manager

(PresseBox) (Potsdam, ) GILUPI GmbH, a developer and manufacturer of medical devices to enrich circulating tumor cells (CTCs) in the human blood stream, announces that Dr. Jens Pfannkuche has been appointed to the position as General Manager of the GILUPI GmbH effective July 2016.

Previously, Dr. Pfannkuche worked in research and development, regulatory affairs, clinical studies, business development and licensing in the medical device industry including B.R.A.H.M.S - part of Thermo Fisher Scientific. Most recently, he served in various functions at B.R.A.H.M.S - part of Thermo Fisher Scientific and as Vice President Clinical Business Development and Regulatory Affairs at BRUKER Daltonik GmbH, where he carried global responsibility for the IVD product line regarding the clinical business development and licensing and the regulatory market access. Dr. Pfannkuche also led the MALDI mass spectrometry Imaging business entering the clinical pathology market. Dr. Pfannkuche studied Biology at the University of North West Wales /UK and University of Otago / NZ and did his doctoral thesis in vibrational spectroscopy at the Polish Academy of Science. He has more than 15 years of experience in the field of implantable medical devices and in vitro diagnostic products in ophthalmology, oncology, infectiology and cardiovascular indications, and has been active in global clinical development and business-to-business licensing and deal-making projects with global medical device and IVD companies.

“I am proud to be part of GILUPI and to enable leveraging GILUPIs potential in liquid biopsy technology for the clinical, industrial and research markets”, says Jens Pfannkuche. “In light of my experience and network in the diagnostic industry regarding break-through technology, I foresee that GILUPI will play a major role in the growing circulating tumor cell market to serve patients with less invasive, cost effective diagnostic solutions in the near future. I would like to thank the shareholders for their trust and I am looking forward to fully utilize the commercial potential of GILUPI in this attractive and growing market“.

Website Promotion


GILUPI GmbH is a medical device company founded in 2006 with focus on the development and production of innovative products for the in vivo isolation of rare cells from the blood circulation. Currently, the main focus of GILUPI is the diagnostics market for cancer.

Individual oncological targeted therapies will become more and more important in tomorrow's personalized medicine. The identification of the right drug for the specific patient is the upcoming challenge. To address this medical need, the application of the GILUPI CellCollector® enriches rare cells (circulating tumor cells - CTCs) by directly "fishing" them in the patient's bloodstream. By using special diagnostic analyses, these isolated cells can be characterized and/or analyzed at a molecular level.

The GILUPI CellCollector® is the first in vivo CTC isolation product worldwide that is CE approved.

For further information visit